Innovate UK

Constructive Bio is a biotechnology company focused on genome rewriting to unlock new possibilities in bioprocesses and biopharmaceuticals. The company transforms living cells into biofactories, producing sustainable materials and therapeutics. By harnessing advanced technologies, Constructive Bio creates virus-resistant organisms and biosynthesizes a range of enzymes, pharmaceuticals, and biomaterials. This innovative approach allows clients to reprogram genetic codes, enabling the creation of natural molecules that were previously inaccessible through conventional biology. Through its unique capabilities, Constructive Bio aims to lead the development of the next generation of sustainable solutions in the life sciences.

Keltic Pharma Therapeutics enhances drug discovery through innovative scientific research, resulting in a healthier future.

Chromatwist specializes in the development of ultraviolet fluorescent dyes designed for bio-sensing and bio-imaging applications. Their innovative molecular technology platform allows for the creation of shifted organic fluorescent dyes that become visible when exposed to UV light, emitting across the entire visible color spectrum. These dyes are characterized by their unique aromatic organic structures, which incorporate donor and acceptor groups capable of absorbing UV light. This versatility enables their use in various diagnostic tests and advanced imaging techniques, including flow cytometry and multiphoton microscopy, thereby enhancing capabilities in the healthcare sector. Chromatwist's modular and scalable chemistry further supports the expansion of their product applications in the life sciences.

Epitopea is a biotechnology company focused on developing innovative immunotherapies for cancer treatment by targeting a new class of tumor-specific antigens. The company employs a proprietary approach that combines immunopeptidomics, mass spectrometry, genomics, and bioinformatics to identify conserved, aberrantly expressed tumor-specific antigens hidden within cancer's non-coding DNA. This technology aims to create therapies that effectively eliminate malignant cells while minimizing damage to healthy tissue, thereby reducing side effects and providing lasting benefits for patients. Research conducted by Drs. Claude Perreault and Pierre Thibault at the Institute for Research in Immunology and Cancer at Université de Montréal has been instrumental in the discovery of these novel antigens, known as Cryptigen™ TSAs, which are shared among patients with the same cancer type.

Theolytics Limited is a clinical-stage biotechnology company founded in 2017 and based in Oxford, United Kingdom. The company specializes in developing oncolytic viral therapies to combat cancer, utilizing a phenotypic screening platform that facilitates the discovery and development of effective, targeted treatment candidates. These therapies are designed for intravenous delivery and tailored to specific patient populations, aiming to provide innovative care options. In addition to advancing its internal pipeline of programs that address both solid and liquid tumors, Theolytics is also focused on forming strategic partnerships to enhance and expedite its pipeline development.

Awen Oncology is a pre-clinical stage pharmaceutical company focused on developing novel cancer therapies. It specializes in targeting 'developmentally-silent oncogenic drivers', which are genes that contribute to cancer growth but are not typically targeted by existing treatments. The company's approach combines expertise in cell and molecular biology with advanced structural biology and in-silico drug screening to rapidly and efficiently identify and develop effective cancer treatments.

MedAnnex Limited is a biotechnology company based in Edinburgh, United Kingdom, focused on developing innovative treatments for patients suffering from autoimmune diseases and cancers. Established in 2009, the company specializes in creating monoclonal antibodies, particularly annexuzlimab, which targets and inhibits annexin-A1. This therapeutic approach aims to modulate both the innate and adaptive immune systems, enhancing treatment options for physicians and improving patient outcomes. MedAnnex is committed to advancing first-in-class antibody therapies that can significantly benefit individuals affected by these challenging health conditions.

ThirtyFiveBio is a biotechnology agency focused on developing innovative protein modulators aimed at treating severe gastrointestinal diseases, which represent a significant unmet clinical need. The company specializes in genetically and pharmacologically validated modulators that facilitate a comprehensive drug discovery program. This program is designed to identify small-molecule modulators of specific proteins, with the potential to impact a wide range of digestive system malignancies. By targeting GPR35 signaling, ThirtyFiveBio's approach aims to provide therapeutic options that may help in preventing tumor growth associated with gastrointestinal cancers.

BiVictriX Therapeutics Ltd. is a UK-based company focused on drug discovery and development, specializing in bispecific antibody drug conjugates aimed at addressing unmet needs in blood cancer treatment. Established in 2016 and located in Alderley Edge, the company employs its proprietary Bi-Cygni technology to create innovative therapeutics, particularly for various types of cancers, including Acute Myeloid Leukaemia. BiVictriX's expertise encompasses oncology, hematological malignancies, immunotherapy, and antibody research, positioning it as a key player in the development of advanced biotherapeutics and drug development initiatives.

IXICO plc, established in 1995 and headquartered in London, specializes in providing data analytics services to the global biopharmaceutical industry. The company focuses on the collection, analysis, management, and reporting of data generated during clinical studies, with a particular emphasis on neurological diseases. IXICO's key technologies include Assessa, a digital platform for clinical decision support, and TrialTracker, a comprehensive imaging service workflow management system. The company's end-to-end imaging services are primarily applied in the fields of Alzheimer's, Parkinson's, Huntington's, multiple sclerosis, cerebrovascular, and progressive supranuclear palsy diseases. IXICO's services are utilized to select patients for clinical trials, assess drug safety and efficacy, and for post-marketing surveillance. The company works with pharmaceutical companies, biotech firms, academia, and medical charities worldwide.

AMPLY Discovery is a biotechnology company focused on utilizing machine learning and synthetic biology to discover novel drug and nutraceutical candidates. By employing a proprietary platform that combines in silico and in vitro approaches, AMPLY aims to develop first-in-class therapeutic molecules to address significant health challenges, including cancer, metabolic diseases, and multi-drug resistant infections. The company’s innovative engine digitizes the natural diversity of life, allowing for the identification of potential drug candidates based on their functional properties. This methodology enhances the predictability and cost-effectiveness of drug discovery, enabling research entities to uncover new treatments for difficult-to-treat diseases.

Concr is a techbio company focused on enhancing cancer treatment by predicting patient responses to various therapies. Utilizing methods from astrophysics, Concr's innovative approach allows for iterative learning from diverse data sources throughout a drug's clinical journey, resulting in accurate multi-modal tumor models without relying on extensive data sets. Its cloud-native platform, FarrSight®, enables researchers to simulate clinical trials, predict therapeutic responses and biomarkers, and conduct standard bioinformatics analyses. This technology aims to identify optimal treatments for individual patients, reduce treatment resistance, and facilitate personalized cancer management. Headquartered in London with a subsidiary in Brisbane, Australia, Concr is backed by several investors, including the University of Cambridge Enterprise and Oncology Ventures.

Mesenbio is a preclinical biopharmaceutical company located at the University of York, specializing in cell-derived therapies. It employs a unique technique known as Cell Line Extracellular Vesicle Release (CLEVR), which enhances the development of treatments by addressing common challenges in extracellular vesicle therapy. The company is focused on creating innovative treatments for conditions such as arthritis, utilizing engineered human stem cells. By unlocking the potential of extracellular vesicles, Mesenbio aims to improve access to effective therapies for musculoskeletal diseases, thereby contributing to advancements in medical treatment.

Pathios Therapeutics Limited is an early-stage drug discovery company based in Oxford, United Kingdom, founded in 2017. The company is dedicated to developing therapies for autoimmune diseases and cancer, focusing on small molecule inhibitors that target the pH-sensing G protein-coupled receptor GPR65. These inhibitors are designed to mitigate the immunosuppressive polarization of immune cells, such as tumor-associated macrophages, which is often stimulated by the acidic microenvironment present in tumors. By employing a rigorous scientific approach that includes insights from human genetics and advanced cellular immunology, Pathios aims to generate novel therapeutics that can address advanced solid tumors and other significant medical needs in immuno-oncology.

ThirtyFiveBio is a biotechnology agency focused on developing innovative protein modulators aimed at treating severe gastrointestinal diseases, which represent a significant unmet clinical need. The company specializes in genetically and pharmacologically validated modulators that facilitate a comprehensive drug discovery program. This program is designed to identify small-molecule modulators of specific proteins, with the potential to impact a wide range of digestive system malignancies. By targeting GPR35 signaling, ThirtyFiveBio's approach aims to provide therapeutic options that may help in preventing tumor growth associated with gastrointestinal cancers.

Stablepharma Ltd specializes in developing innovative processes for vaccine stabilization, focusing on its technology platform, StablevaX™, which transforms existing approved vaccines, therapeutics, and diagnostics into thermostable products that do not require refrigeration. This advancement addresses the global challenges associated with cold chain logistics, allowing for efficient and waste-free vaccine delivery. The company has identified up to 60 vaccine candidates suitable for its technology and collaborates with global vaccine manufacturers, academic institutions, and non-governmental organizations to enhance its pipeline of thermostable products. Founded in 2012 and based in Bath, United Kingdom, Stablepharma aims to reduce costs and carbon emissions while expanding access to vaccines for both children and adults.

AstronauTx is a biotechnology company focused on developing treatments for Alzheimer's disease and other neurodegenerative conditions. The company aims to restore the normal functioning of astrocytes, which are crucial cells in the brain that support neuronal activity, metabolism, and the integrity of the blood-brain barrier. In conditions such as dementia, astrocytes can become dysfunctional, leading to neurotoxicity and exacerbating disease progression. By targeting astrocyte homeostasis, AstronauTx seeks to enable healthcare professionals to effectively address the underlying mechanisms of neurotoxicity associated with these diseases, ultimately improving treatment options for patients suffering from dementia and related disorders.

Intellegens specializes in applying artificial intelligence and machine learning to enhance innovation in various fields, including materials, chemicals, and manufacturing. The company’s flagship software, Alchemite™, originated from research at the University of Cambridge and is designed to train deep neural networks using sparse and noisy data, where conventional methods often struggle. By utilizing Alchemite™, users can conduct analyses through a user-friendly web interface and leverage advanced graphical tools, which streamline the integration of AI into existing workflows and tools. This capability allows clients to achieve significant improvements, such as reducing the number of required experiments by up to 90%, thereby saving time and costs. Intellegens has successfully implemented its technology in diverse applications, including drug discovery, materials development, and manufacturing processes, enabling clients to extract greater value from incomplete datasets.

Plasticell is a biotechnology company focused on developing innovative therapeutics through advanced cell culture and drug discovery platforms. The company specializes in elucidating the biochemical mechanisms that regulate the proliferation and differentiation of stem cells, which are essential for tissue development and repair. By testing a wide range of cell culture variables, Plasticell aims to establish optimal laboratory protocols for various applications in cell biology, gene transduction, protein production, and drug screening. This approach enables researchers to create novel small molecule drugs that promote regenerative medicine and improve therapeutic outcomes.

Autolomous Ltd, founded in 2019 and based in Mayfair, United Kingdom, specializes in developing software solutions for manufacturers of cell and gene therapies. Its flagship platform, autoloMATE®, is a cloud-native system that provides comprehensive support for Advanced Therapies and Vector manufacturing processes. The software facilitates the scheduling of patient cell collections, the transport of these cells to production sites, and the tracking of manufacturing processes to ensure compliance with regulatory standards. It also supports the legal release and timely delivery of patient-specific medicines. The highly configurable platform allows clients to customize workflows and integrates seamlessly with existing systems. Autolomous emphasizes data security by utilizing blockchain technology to maintain the integrity of manufacturing data. The company adheres to strict regulatory guidelines and has achieved several ISO certifications, reflecting its commitment to quality management and environmental standards.

The Cell and Gene Therapy Catapult is a UK-based center dedicated to fostering innovation in the cell and gene therapy sector. Supported by Innovate UK, its primary objective is to accelerate the development of commercially viable therapies by assisting organizations in translating early-stage research into market-ready products. The Catapult employs over 120 experts in cell and gene therapy and features advanced laboratories for development and viral vector research. Additionally, it is in the process of establishing a £55 million large-scale Good Manufacturing Practice (GMP) manufacturing center to facilitate the market introduction of cell and gene therapies both in the UK and internationally. By offering expertise in clinical trials, process development, manufacturing, regulatory affairs, health economics, and market access, the Catapult aims to help research organizations achieve full-scale commercialization of their therapies.

Lindus Health is a clinical research organization focused on delivering comprehensive clinical trial services for health and biotech companies. The company offers a range of solutions, including ethics and IRB submission, trial monitoring, data management, biostatistics, regulatory support, and payer affairs. By utilizing a proprietary software platform, Lindus Health automates various aspects of the clinical trial workflow, which streamlines operations and minimizes manual inefficiencies. This platform also facilitates access to electronic health records, enhancing patient recruitment and clinical data capture. Furthermore, Lindus Health leverages real-world patient data to improve trial design and execution, ultimately aiming to accelerate the clinical trial process while reducing risks and costs associated with trial failures.

Senisca is a senotherapeutics company established in 2020, focused on developing anti-aging oligonucleotide therapeutics. The company aims to provide innovative pharmaceutical treatments for age-related chronic diseases by creating a new generation of oligonucleotide-based interventions. These therapeutics target the underlying mechanisms of aging, restoring the ability of cells to regulate gene expression effectively. By rejuvenating aged cells, Senisca seeks to improve healthspan and address both the diseases and aesthetic manifestations of aging, ultimately enabling individuals to live healthier for longer periods.

DeepMirror is a software platform that integrates human expertise with artificial intelligence to enhance drug discovery processes. The company specializes in predicting the properties of molecules and their affinity for various targets, thereby streamlining the research and development efforts of biopharmaceutical teams. By employing structured perception and feature fusion techniques, DeepMirror's platform delivers advanced 3D insights while maintaining low power consumption. This capability simplifies the analysis of complex data, ultimately allowing researchers to focus on the most promising drug candidates and conduct fewer experiments, leading to more efficient drug development.

Lightox specializes in developing advanced molecular tools for imaging, therapeutics, and assay development, focusing on innovative cancer treatments. The company has created a range of light-activated drug compounds designed to selectively target and eliminate tumor cells while minimizing harm to surrounding healthy tissue. Their unique fluorescent probes are smaller than any other products currently available, allowing for versatile applications in research and clinical settings. These probes can function as freely-moving agents that easily integrate into cells, or they can be customized with flexible linkers to meet specific research requirements. Lightox aims to enhance patient outcomes by providing more efficient cancer treatment options.

EnsiliTech is a biopharmaceutical company focused on preserving the integrity of vaccines and other biological materials. It has developed a healthcare technology that aims to prevent vaccine spoilage through a novel ensilication process. This technology involves the growth of protective silica nanoshells on the surface of vaccine components, which helps safeguard a variety of biomolecules from environmental degradation. By enhancing the shelf-life of vaccines, EnsiliTech's platform enables clients to minimize wastage and improve global vaccine accessibility.

EnsiliTech is a biopharmaceutical company focused on preserving the integrity of vaccines and other biological materials. It has developed a healthcare technology that aims to prevent vaccine spoilage through a novel ensilication process. This technology involves the growth of protective silica nanoshells on the surface of vaccine components, which helps safeguard a variety of biomolecules from environmental degradation. By enhancing the shelf-life of vaccines, EnsiliTech's platform enables clients to minimize wastage and improve global vaccine accessibility.

Healthera Ltd., established in 2015 and headquartered in Cambridge, UK, specializes in developing digital health solutions. Its flagship product, Healthera, is a pharmacy-integrated medication management app that offers automatic prescription reminders, smart labelling, scheduling, health condition tracking, and professional advice from pharmacists. Additionally, Healthera operates a healthcare marketplace that connects patients with local pharmacies and GPs, enabling faster medicine delivery and personalized care. The company partners with over 1000 pharmacies and Clinical Commissioning Groups (CCGs) across the UK, reaching over 20 million people. Its technology is accredited by NHS Digital and aims to improve prescribing efficiency, patient experience, and reduce wastage within the NHS.

The National Biofilms Innovation Centre (NBIC) serves as a collaborative hub uniting academia, industry, government, and public policy to address the challenges posed by biofilms, which significantly impact global economic activity across sectors such as food, health, shipping, clean water, and energy. Supported by funding from the BBSRC, Innovate UK, and Hartree Centre, NBIC's mission focuses on fostering a network for research and innovation that catalyzes partnerships with industry to drive breakthrough innovations. The Centre facilitates the exploration of unmet needs and the exchange of ideas through various initiatives, including roadmaps, workshops, and conferences. Additionally, NBIC is dedicated to nurturing the next generation of scientists through PhD and Post-Doc programs, alongside entrepreneurial training, aimed at enhancing their expertise and understanding of the commercial landscape while promoting the creation of new start-ups.

The Medicines Discovery Catapult is the centre of national expertise for the discovery of medicines.

iEthico is a company focused on resolving drug supply and shortage issues through a digital supply chain platform. This platform streamlines the sourcing of medicines by providing automated, cloud-based services that track data and generate essential insights. It alerts users to potential shortages and connects pharmacists with reliable suppliers, thereby empowering them to manage their inventory effectively. The service features an MHRA-approved automated regulatory process that minimizes paperwork, saving time for pharmacies. Following successful market testing, iEthico's solution is currently being rolled out to community pharmacies and NHS Trusts across the UK, aiming to enhance the efficiency of medicine distribution and reduce costs for healthcare providers.

LabGenius Ltd is a biopharmaceutical company based in London that focuses on discovering new biological molecules through the integration of artificial intelligence, automation, and synthetic DNA. Founded in 2012, the company has developed a robotic platform known as EVA, which acts as a robot scientist capable of designing, conducting, and learning from its own experiments. LabGenius specializes in developing next-generation protein therapeutics aimed at addressing unmet medical needs, including conditions like Inflammatory Bowel Disease. Their innovative approach utilizes advanced machine learning and synthetic biology to engineer the properties of protein drugs, enhancing attributes such as protease stability and tissue penetration. This technology enables the efficient creation of protein therapeutics, providing physicians with access to cutting-edge treatments developed through robotic automation.

Metallo Bio's focus is on the development of two lead chemicals that represent a pioneering new class of antibiotics, with the goal of addressing the rising issue of antimicrobial resistance.

aTen Therapeutics is a biotechnology company focused on developing innovative therapeutic antibodies aimed at treating major diseases, particularly cancer. The company's unique approaches target a fundamental control pathway associated with various diseases, enabling the development of treatments that can significantly improve patient outcomes. aTen Therapeutics' antibodies are designed to inhibit cancer cell growth, invasion, and metastasis across multiple tumor models. By combining these antibodies with anti-cancer agents, the company seeks to enhance the efficacy of cancer treatments and provide healthcare professionals with effective tools to improve the lives of cancer patients while protecting against the progression of metastases. The management team possesses extensive experience in the biopharmaceutical industry, emphasizing the company's commitment to advancing medical science and patient care.

AMPLY Discovery is a biotechnology company focused on utilizing machine learning and synthetic biology to discover novel drug and nutraceutical candidates. By employing a proprietary platform that combines in silico and in vitro approaches, AMPLY aims to develop first-in-class therapeutic molecules to address significant health challenges, including cancer, metabolic diseases, and multi-drug resistant infections. The company’s innovative engine digitizes the natural diversity of life, allowing for the identification of potential drug candidates based on their functional properties. This methodology enhances the predictability and cost-effectiveness of drug discovery, enabling research entities to uncover new treatments for difficult-to-treat diseases.

Eleven Therapeutics is a biotechnology company focused on advancing RNA-based therapies through the integration of artificial intelligence and innovative drug development techniques. The company specializes in developing extended durability messenger RNA (mRNA) therapeutics aimed at addressing unmet medical needs in metabolic, endocrinologic, and infectious diseases. By employing proprietary high-throughput AI-enabled screening platforms, Eleven Therapeutics enhances the stability and targeted delivery of its therapeutic molecules. Its signature technology, SCSI-RNA, represents a programmable approach that allows for precise targeting of various diseases and biological targets. Through these advancements, Eleven Therapeutics is positioned to transform the landscape of RNA drug development, offering promising solutions for complex health challenges.

DeepMirror is a software platform that integrates human expertise with artificial intelligence to enhance drug discovery processes. The company specializes in predicting the properties of molecules and their affinity for various targets, thereby streamlining the research and development efforts of biopharmaceutical teams. By employing structured perception and feature fusion techniques, DeepMirror's platform delivers advanced 3D insights while maintaining low power consumption. This capability simplifies the analysis of complex data, ultimately allowing researchers to focus on the most promising drug candidates and conduct fewer experiments, leading to more efficient drug development.

Metallo Bio's focus is on the development of two lead chemicals that represent a pioneering new class of antibiotics, with the goal of addressing the rising issue of antimicrobial resistance.

Senisca is a senotherapeutics company established in 2020, focused on developing anti-aging oligonucleotide therapeutics. The company aims to provide innovative pharmaceutical treatments for age-related chronic diseases by creating a new generation of oligonucleotide-based interventions. These therapeutics target the underlying mechanisms of aging, restoring the ability of cells to regulate gene expression effectively. By rejuvenating aged cells, Senisca seeks to improve healthspan and address both the diseases and aesthetic manifestations of aging, ultimately enabling individuals to live healthier for longer periods.

NRG Therapeutics is a drug discovery company established in 2018 that specializes in developing therapeutic approaches aimed at restoring mitochondrial function to address neurodegenerative diseases, including Parkinson’s disease, Alzheimer’s disease, and motor neuron disease. The company focuses on creating novel medicines that preserve mitochondrial function and halt disease progression. With a team experienced in neuroscience drug discovery, NRG Therapeutics is initially concentrating on the discovery and development of brain-penetrant inhibitors of the mitochondrial permeability transition pore specifically for Parkinson’s disease. This strategic focus is intended to empower physicians with effective treatment options for patients suffering from chronic neurodegenerative disorders.

Kynos Therapeutics is a biotechnology company focused on developing KMO inhibitors to address unmet medical needs in inflammation, immunity, and metabolism. The company aims to block the action of the enzyme KMO, which plays a crucial role in regulating systemic inflammation and is implicated in various medical conditions. By providing new therapies that target this key enzyme, Kynos Therapeutics seeks to offer innovative treatments for conditions where there is a significant demand for effective medicines.

Medwise.ai offers a customizable search platform designed to support clinical decision-making for healthcare professionals. Utilizing natural language processing and artificial intelligence, the platform enables doctors to efficiently access and organize medical knowledge. By leveraging real-world data, Medwise.ai provides valuable intelligence and insights to various stakeholders within the healthcare ecosystem. This innovative approach aims to enhance the professional capabilities of doctors, ultimately improving patient care and outcomes.

Eleven Therapeutics is a biotechnology company focused on advancing RNA-based therapies through the integration of artificial intelligence and innovative drug development techniques. The company specializes in developing extended durability messenger RNA (mRNA) therapeutics aimed at addressing unmet medical needs in metabolic, endocrinologic, and infectious diseases. By employing proprietary high-throughput AI-enabled screening platforms, Eleven Therapeutics enhances the stability and targeted delivery of its therapeutic molecules. Its signature technology, SCSI-RNA, represents a programmable approach that allows for precise targeting of various diseases and biological targets. Through these advancements, Eleven Therapeutics is positioned to transform the landscape of RNA drug development, offering promising solutions for complex health challenges.

Cytochroma manufacture genetically diverse stem cell-derived models to predict the safety and effect of drugs in a global population. Cytochroma’s automated cell manufacture, physiologically relevant models and rapid screening platform makes preclinical testing faster, safer and smarter.

Vamstar operates a B2B healthcare supply chain platform that addresses inefficiencies in the sourcing and procurement processes for medical devices and pharmaceuticals. By utilizing advanced data automation technologies such as machine learning, Vamstar aggregates demand from millions of sources, creating a comprehensive marketplace that connects buyers, including hospitals and health systems, with a vast network of suppliers. The platform provides real-time analytics and valuable tools for search and bid development, allowing users to quickly identify suitable opportunities and finalize transactions. With access to a significant volume of global demand and millions of contracts, Vamstar simplifies the procurement process, helping healthcare organizations reduce costs and improve access to essential products and services. The company is dedicated to building a digital marketplace that fosters innovation in healthcare and is supported by leading investors in the field.

Chromatwist specializes in the development of ultraviolet fluorescent dyes designed for bio-sensing and bio-imaging applications. Their innovative molecular technology platform allows for the creation of shifted organic fluorescent dyes that become visible when exposed to UV light, emitting across the entire visible color spectrum. These dyes are characterized by their unique aromatic organic structures, which incorporate donor and acceptor groups capable of absorbing UV light. This versatility enables their use in various diagnostic tests and advanced imaging techniques, including flow cytometry and multiphoton microscopy, thereby enhancing capabilities in the healthcare sector. Chromatwist's modular and scalable chemistry further supports the expansion of their product applications in the life sciences.

Glamorous AI develops an artificial intelligence-based drug discovery platform that focuses on low-data scenarios in pharmaceutical research. The platform utilizes AI to identify and optimize novel chemical compounds, facilitating the discovery of new medicines by analyzing prior experimental results. It is designed to handle sparse, noisy, and small datasets, making it particularly effective for tackling complex drug discovery challenges. By leveraging a large repository of pre-trained and customizable AI models, Glamorous AI enables researchers to screen extensive chemical libraries and address novel and first-in-class therapeutic targets, ultimately driving innovation in drug development and contributing to the advancement of treatments for various diseases.

Arecor Limited is a biopharmaceutical company based in Cambridge, United Kingdom, specializing in stabilization technology solutions for the pharmaceutical and biotech sectors. Founded in 2006, Arecor utilizes its innovative formulation technology platform to enhance the commercial value and utility of proteins across various applications, including vaccines and therapeutic proteins. The company develops products targeting infectious diseases, diabetes, oncology, immunology, and hormone replacement therapies. It focuses on reformulating existing therapies to improve their stability and efficacy, enabling self-administration for patients through pre-filled syringes and injection pens. Notably, Arecor works on high-concentration formulations of antibodies, such as Trastuzumab and Rituximab, to improve treatment for conditions like breast cancer and non-Hodgkin’s lymphoma. Additionally, Arecor creates stable liquid formulations for vaccines and biological therapies, addressing challenges in degradation and stability. Through partnerships with leading pharmaceutical companies, Arecor aims to deliver advanced reformulations that enhance treatment options for patients.

Senisca is a senotherapeutics company established in 2020, focused on developing anti-aging oligonucleotide therapeutics. The company aims to provide innovative pharmaceutical treatments for age-related chronic diseases by creating a new generation of oligonucleotide-based interventions. These therapeutics target the underlying mechanisms of aging, restoring the ability of cells to regulate gene expression effectively. By rejuvenating aged cells, Senisca seeks to improve healthspan and address both the diseases and aesthetic manifestations of aging, ultimately enabling individuals to live healthier for longer periods.

Camallergy Limited, based in Cambridge, United Kingdom, is a biopharmaceutical company established in 2015 that focuses on developing and manufacturing oral immunotherapy drugs and other pharmaceutical products specifically for food allergies. The company's primary offering is a novel oral immunotherapy designed to treat peanut allergies, which aims to provide patients with "bite-proof" protection within 14 weeks of therapy. This patient-centric treatment addresses the urgent needs of millions suffering from food allergies and is rooted in clinical research conducted at Cambridge University Hospitals NHS Foundation Trust. Camallergy's unique intellectual property and treatment regimen exemplify its commitment to improving the quality of life for individuals affected by these allergies.

CN Bio Innovations Ltd, established in 2008 and headquartered in Cambridge, UK, specializes in developing and providing Organ-on-Chip devices to pharmaceutical and biotech companies. These devices enable more accurate preclinical drug testing by replicating human organ functions in vitro. CN Bio's offerings include microphysiological systems and consumables, used to analyze novel compounds, assess toxicity and safety, and support research scientists in various fields such as oncology, infectious diseases, metabolism, and inflammation. The company's flagship product, the LiverChip platform, features a full viral lifecycle model of hepatitis B, currently employed in drug discovery collaborations with leading pharmaceutical and biotech companies. CN Bio's work is backed by prestigious grants and partnerships with academic institutions, aiming to accelerate the development of breakthrough therapies for serious human diseases.

Vamstar operates a B2B healthcare supply chain platform that addresses inefficiencies in the sourcing and procurement processes for medical devices and pharmaceuticals. By utilizing advanced data automation technologies such as machine learning, Vamstar aggregates demand from millions of sources, creating a comprehensive marketplace that connects buyers, including hospitals and health systems, with a vast network of suppliers. The platform provides real-time analytics and valuable tools for search and bid development, allowing users to quickly identify suitable opportunities and finalize transactions. With access to a significant volume of global demand and millions of contracts, Vamstar simplifies the procurement process, helping healthcare organizations reduce costs and improve access to essential products and services. The company is dedicated to building a digital marketplace that fosters innovation in healthcare and is supported by leading investors in the field.

Vamstar operates a B2B healthcare supply chain platform that addresses inefficiencies in the sourcing and procurement processes for medical devices and pharmaceuticals. By utilizing advanced data automation technologies such as machine learning, Vamstar aggregates demand from millions of sources, creating a comprehensive marketplace that connects buyers, including hospitals and health systems, with a vast network of suppliers. The platform provides real-time analytics and valuable tools for search and bid development, allowing users to quickly identify suitable opportunities and finalize transactions. With access to a significant volume of global demand and millions of contracts, Vamstar simplifies the procurement process, helping healthcare organizations reduce costs and improve access to essential products and services. The company is dedicated to building a digital marketplace that fosters innovation in healthcare and is supported by leading investors in the field.

NovaBiotics Ltd. is a clinical-stage biotechnology company based in Aberdeen, United Kingdom, with an additional location in Raleigh, North Carolina. Founded in 2004, the company specializes in the design and development of innovative anti-infective therapies for medically unmet diseases. Its product pipeline includes Novexatin, a cationic antifungal peptide for treating onychomycosis, and Lynovex, a dual-therapy for cystic fibrosis-related lung diseases. Additionally, NovaBiotics offers other antifungal peptides such as Novamycin for conditions like aspergillosis and cryptococcosis, as well as Novarifyn, an antibacterial peptide targeting bacterial infections. The company’s proprietary anti-infective peptide platform allows for the development of both antifungal and antibacterial candidates, addressing serious health challenges related to drug-resistant infections.

Intellegens specializes in applying artificial intelligence and machine learning to enhance innovation in various fields, including materials, chemicals, and manufacturing. The company’s flagship software, Alchemite™, originated from research at the University of Cambridge and is designed to train deep neural networks using sparse and noisy data, where conventional methods often struggle. By utilizing Alchemite™, users can conduct analyses through a user-friendly web interface and leverage advanced graphical tools, which streamline the integration of AI into existing workflows and tools. This capability allows clients to achieve significant improvements, such as reducing the number of required experiments by up to 90%, thereby saving time and costs. Intellegens has successfully implemented its technology in diverse applications, including drug discovery, materials development, and manufacturing processes, enabling clients to extract greater value from incomplete datasets.

Kuano Ltd specializes in developing quantum and AI solutions aimed at molecular design, particularly in the fields of drug discovery and development. Founded in 2020 and based in London, the company integrates quantum simulation with machine learning to create effective enzyme inhibitors. Its innovative discovery platform employs target quantum mapping alongside AI-driven chemistry, facilitating the faster and more efficient development of superior drug candidates. Kuano's technology is applicable across several sectors, including pharmaceuticals, crop protection, and industrial chemistry, ultimately enhancing the quality of new therapeutics while reducing the time required for their discovery.

Medwise.ai offers a customizable search platform designed to support clinical decision-making for healthcare professionals. Utilizing natural language processing and artificial intelligence, the platform enables doctors to efficiently access and organize medical knowledge. By leveraging real-world data, Medwise.ai provides valuable intelligence and insights to various stakeholders within the healthcare ecosystem. This innovative approach aims to enhance the professional capabilities of doctors, ultimately improving patient care and outcomes.

Vamstar operates a B2B healthcare supply chain platform that addresses inefficiencies in the sourcing and procurement processes for medical devices and pharmaceuticals. By utilizing advanced data automation technologies such as machine learning, Vamstar aggregates demand from millions of sources, creating a comprehensive marketplace that connects buyers, including hospitals and health systems, with a vast network of suppliers. The platform provides real-time analytics and valuable tools for search and bid development, allowing users to quickly identify suitable opportunities and finalize transactions. With access to a significant volume of global demand and millions of contracts, Vamstar simplifies the procurement process, helping healthcare organizations reduce costs and improve access to essential products and services. The company is dedicated to building a digital marketplace that fosters innovation in healthcare and is supported by leading investors in the field.

Mosaic Therapeutics is reshaping the interface of computational and experimental medicine to power new medicines for patients.

Symbiosis Pharmaceutical Services Limited is a contract manufacturer specializing in sterile pharmaceuticals for clinical trials, based in Stirling, United Kingdom. Established in 2011 to address the growing global demand for niche sterile manufacturing, the company provides filling and finishing services tailored to biotechnology and specialty pharmaceutical companies. Its purpose-built facility is designed to accommodate both biologic and small molecule production, focusing on small-scale injectable products. Symbiosis differentiates itself by offering rapid access to manufacturing slots and quick release of drug products, enabling clients to meet tight timelines effectively. By maintaining high standards of regulatory compliance, Symbiosis supports the evolving needs of its clients in the pharmaceutical sector.

LUNAC Therapeutics is focused on developing advanced oral anticoagulant medications aimed at treating and preventing serious thrombotic events. The company’s innovative drugs are designed to reduce the risk of bleeding in patients, which allows healthcare providers to safely escalate dosages for high-risk individuals. By addressing a critical need in the management of thrombotic conditions, LUNAC Therapeutics aims to improve patient outcomes and enhance the overall safety of anticoagulant therapies.

Ixaka is a private UK-based cell and gene therapy company with operations in the UK, Spain, and France. The company leverages proprietary technologies to enhance the body's natural ability to heal, focusing on the development of advanced cell-based therapeutics for serious diseases. Ixaka's innovative approaches include concentrated multi-cell therapies and targeted nanoparticles that aim to deliver curative cells directly to the site of disease and improve their therapeutic efficacy. This platform has potential applications across a variety of conditions, including oncology, cardiovascular, neurological, ocular diseases, and genetic disorders. The ultimate goal of Ixaka's therapies is to reduce pain, improve mobility, and enhance overall patient outcomes.

The Cell and Gene Therapy Catapult is a UK-based center dedicated to fostering innovation in the cell and gene therapy sector. Supported by Innovate UK, its primary objective is to accelerate the development of commercially viable therapies by assisting organizations in translating early-stage research into market-ready products. The Catapult employs over 120 experts in cell and gene therapy and features advanced laboratories for development and viral vector research. Additionally, it is in the process of establishing a £55 million large-scale Good Manufacturing Practice (GMP) manufacturing center to facilitate the market introduction of cell and gene therapies both in the UK and internationally. By offering expertise in clinical trials, process development, manufacturing, regulatory affairs, health economics, and market access, the Catapult aims to help research organizations achieve full-scale commercialization of their therapies.

Symbiosis Pharmaceutical Services Limited is a contract manufacturer specializing in sterile pharmaceuticals for clinical trials, based in Stirling, United Kingdom. Established in 2011 to address the growing global demand for niche sterile manufacturing, the company provides filling and finishing services tailored to biotechnology and specialty pharmaceutical companies. Its purpose-built facility is designed to accommodate both biologic and small molecule production, focusing on small-scale injectable products. Symbiosis differentiates itself by offering rapid access to manufacturing slots and quick release of drug products, enabling clients to meet tight timelines effectively. By maintaining high standards of regulatory compliance, Symbiosis supports the evolving needs of its clients in the pharmaceutical sector.

Nanna Therapeutics Limited is a biotechnology company based in Cambridge, United Kingdom, focused on developing drugs for age-related diseases, including mitochondrial, neurodegenerative, cardiovascular/metabolic, joint/tissue diseases, and cancer. Founded in 2012, the company aims to address the unmet medical needs in these areas by targeting fundamental cellular processes to create innovative treatments. Nanna Therapeutics employs a proprietary platform known as the Totally Integrated Medicines Engine (TIME), which utilizes advanced technologies such as microfluidics, nanofabrication, and artificial intelligence to enhance drug discovery. This platform enables the rapid creation and functional screening of millions of novel compounds, thereby accelerating the development of transformative medicines for conditions that currently lack effective therapies. As of April 2020, Nanna Therapeutics operates as a subsidiary of Astellas Pharma Europe Ltd.

Epsilogen Ltd is an immuno-oncology company based in London, United Kingdom, founded in 2016. The company specializes in developing immunoglobulin E (IgE) antibodies aimed at treating cancer. Epsilogen offers a portfolio of IgE candidates that specifically target cancer antigens such as HER2, EGFR, and PD-L1. Its innovative IgE platform supports the development and validation of novel antibodies, allowing for enhanced potency, improved tumor access, and a prolonged presence in tissue. This focus on IgE-based therapies positions Epsilogen to provide effective treatment options for patients with solid tumors.

A UK pharmaceutical development company, AKL Research & Development Ltd (AKLRD) is committed to transforming patient’s lives through innovative solutions that meet unmet needs.AKLRD is developing novel therapeutics for inflammatory diseases with a high unmet need, including osteoarthritis, Alzheimer’s, rheumatoid arthritis & scleroderma, a rare connective tissue disease.

Roslin Cells is the parent company of Roslin Cell Therapies. Based in Edinburgh, UK Roslin Cell Therapies has a wealth of expertise, capabilities and industry recognition in process translation to GMP, development, optimization, scale up and the GMP manufacture of Cell Therapy and Advanced Therapy Medicinal Products (ATMPs).

RoslinCT is a UK-based Contract Development and Manufacturing Organisation (CDMO) that specializes in cell and gene therapy. The company offers a range of services tailored for organizations developing cell-based therapeutic products. Its expertise encompasses tissue procurement, cryopreservation studies, pre-clinical studies, and analytical development. By providing these services, RoslinCT enables its clients to create compliant, sustainable, and cost-effective therapies, supporting advancements in the field of regenerative medicine.

Medherant Limited is a clinical-stage company based in Coventry, United Kingdom, focused on developing innovative treatments for pain and central nervous system diseases through its advanced transdermal drug delivery technology. Founded in 2014 by Professor David Haddleton and the University of Warwick, Medherant has created the TEPI Patch, a novel transdermal system that utilizes a unique adhesive to enhance drug delivery while overcoming challenges associated with metabolism, gastrointestinal toxicity, and low bioavailability. Unlike traditional patch technologies that may have limited drug loading capacities, Medherant's approach allows for higher concentrations of medications and faster release rates. This method addresses the shortcomings of topical creams and gels, which often lack precise dose control, thereby providing an effective solution for delivering a broader range of pharmaceutical products.

Optibrium is a software company that specializes in providing innovative solutions for small molecule design, optimization, and data analysis, aimed at enhancing the drug discovery process. Founded in 2009 and headquartered in Cambridge, UK, with an additional office in Boston, US, the company’s flagship product, StarDrop, is a comprehensive and user-friendly software suite that facilitates the integration of data, predictive modeling, and decision-making in research. This tool enables users to streamline their workflow from data analysis to compound synthesis, thereby increasing the speed and efficiency of drug discovery. Optibrium collaborates with a diverse range of clients, including leading pharmaceutical companies, biotech firms, and academic institutions, to continuously develop new technologies and improve productivity in drug development.

Metrion Biosciences Ltd is a contract research organization based in Cambridge, United Kingdom, specializing in drug discovery services for pharmaceutical and bioscience clients globally. Established in 2015, the company provides a range of preclinical screening services, with a focus on ion channel screening, cardiac safety profiling, neuroscience assays, and translational assays. Metrion's platform offers skilled electrophysiology services in various formats, supporting medicinal chemistry optimization. The organization employs flexible business models, allowing clients to choose between fee-for-service and collaborative options, as well as access to integrated drug discovery services tailored to the specific needs of each program.

Ubiquigent Limited is a biotechnology company based in Dundee, United Kingdom, founded in 2009. It specializes in the development and supply of high-quality reagents, kits, and drug discovery assay development services, primarily targeting the life science research community. Ubiquigent focuses on protein degradation and the ubiquitin signaling systems, providing services that support drug discovery efforts aimed at developing novel deubiquitylase (DUB) enzyme inhibitors. The company works closely with academic researchers and pharmaceutical scientists, aiding in the exploration of therapeutic applications for DUB modulators in areas with significant unmet medical needs. Ubiquigent is committed to generating intellectual property through its innovative drug discovery programs, which include optimizing compounds that target the ubiquitin cascade.

Elasmogen Ltd is a biopharmaceutical company based in Aberdeen, United Kingdom, focused on developing innovative therapies for inflammatory eye diseases and other autoimmune conditions. The company specializes in soloMERs, which are small, stable proteins derived from variable new-antigen receptors (VNARs) found in sharks. These next-generation therapeutics are unique due to their evolutionary lineage, allowing them to bypass the complex patent landscape associated with traditional antibodies. Elasmogen's pipeline includes programs aimed at autoimmune-mediated inflammation, as well as soloMER-drug conjugates designed for enhanced therapeutic delivery. Additionally, the company has developed NDure, a humanized clinical candidate that extends the plasma half-life of fused partner molecules. Elasmogen holds a strong intellectual property position with over 20 granted patents in various regions, supported by strategic partnerships with Almac Discovery Ltd and Merck Inc. Founded in 2014, the company is dedicated to advancing the treatment options available for patients suffering from sight-threatening and inflammatory diseases.

Almac Group is a contract development and manufacturing organization that provides a comprehensive range of services to pharmaceutical and biotech companies worldwide. Established over 40 years ago and privately owned, the company specializes in research and development, biomarker discovery, active pharmaceutical ingredient (API) manufacturing, formulation development, clinical trial supply, and companion diagnostic development. Headquartered in Craigavon, Northern Ireland, Almac operates additional facilities in the UK, Ireland, the US, and Asia. With a workforce exceeding 4,500 employees, the company is committed to continuous investment in its service offerings, including advancements in biomarker and companion diagnostics, clinical trial data management, and biocatalytic API manufacturing. Almac Discovery, a division of the group, is dedicated to the research and development of innovative cancer treatments, focusing on early-stage partnerships for further program development.

Phico Therapeutics Limited is a biotechnology company based in Bourn, United Kingdom, focused on developing innovative antibiotics to combat antibacterial resistance. Utilizing its SASPject platform, the company delivers anti-bacterial proteins, including small acid-soluble spore proteins, to specific bacterial species through targeted non-delivery vehicles. Phico's product pipeline includes SASPject PT3, an antibiotic aimed at Pseudomonas aeruginosa; SASPject PT4 and PT5, designed for systemic use against Klebsiella pneumonia and Escherichia coli; and SASPject PT1.2, which targets Staphylococcus aureus. Additionally, the company is developing an intravenous-engineered bacteriophage drug intended to treat ventilator-associated pneumonia by using engineered bacterial viruses along with antibacterial proteins to inhibit bacterial reproduction and toxin release. Founded in 2000, Phico Therapeutics is committed to advancing solutions for pressing healthcare challenges posed by antibiotic resistance.

Arecor Limited is a biopharmaceutical company based in Cambridge, United Kingdom, specializing in stabilization technology solutions for the pharmaceutical and biotech sectors. Founded in 2006, Arecor utilizes its innovative formulation technology platform to enhance the commercial value and utility of proteins across various applications, including vaccines and therapeutic proteins. The company develops products targeting infectious diseases, diabetes, oncology, immunology, and hormone replacement therapies. It focuses on reformulating existing therapies to improve their stability and efficacy, enabling self-administration for patients through pre-filled syringes and injection pens. Notably, Arecor works on high-concentration formulations of antibodies, such as Trastuzumab and Rituximab, to improve treatment for conditions like breast cancer and non-Hodgkin’s lymphoma. Additionally, Arecor creates stable liquid formulations for vaccines and biological therapies, addressing challenges in degradation and stability. Through partnerships with leading pharmaceutical companies, Arecor aims to deliver advanced reformulations that enhance treatment options for patients.

Sentinel Oncology Limited is a drug discovery company based in Cambridge, United Kingdom, founded in 2005. The company focuses on developing and commercializing therapeutics aimed at treating cancer, particularly for patients facing unmet medical needs. Sentinel Oncology's research and development pipeline includes innovative programs such as a treatment targeting Checkpoint Kinase 1, which is activated in response to DNA damage and replication stress, and a novel approach to treating metastatic breast cancer through the inhibition of S6K1. The company is advancing a strategy known as "Targeted Synergy," designed to enhance the therapeutic index by delivering drug effects directly to tumors. By fostering partnerships with the biotechnology and pharmaceutical industries, Sentinel Oncology aims to maximize the value of its drug candidates and contribute to improved cancer treatments.

Vitamica Ltd is a diagnostic technology company based in Bristol, United Kingdom, founded in 2018 as a spin-out from the University of Bristol. The company specializes in rapid antimicrobial susceptibility testing (AST) that determines the effectiveness of antibiotics against pathogenic bacteria. By utilizing advanced optical technology, Vitamica's diagnostic method detects nanoscale fluctuations in live bacteria, providing clinicians with crucial information to make informed decisions regarding antibiotic treatment. With an expanding intellectual property portfolio, Vitamica aims to capitalize on opportunities in the healthcare, veterinary, and pharmaceutical sectors, positioning itself as a notable innovator in the field of antimicrobial susceptibility testing.

MGB Biopharma Limited is a biopharmaceutical company based in Bellshill, United Kingdom, specializing in the development of a new class of anti-infective medicines derived from minor groove binder compounds. Established in 2009, the company focuses on creating small molecules with specific antibacterial properties to combat both multi-resistant and susceptible Gram-positive bacteria. One of its key products, MGB-BP-3, is an antibacterial agent designed for the oral treatment of Clostridium difficile-associated disease. MGB Biopharma aims to address the challenges of antibiotic resistance by employing a novel mode of action that targets bacteria lacking inherent resistance mechanisms, offering a promising approach to treating bacterial infections effectively.

Symbiosis Pharmaceutical Services Limited is a contract manufacturer specializing in sterile pharmaceuticals for clinical trials, based in Stirling, United Kingdom. Established in 2011 to address the growing global demand for niche sterile manufacturing, the company provides filling and finishing services tailored to biotechnology and specialty pharmaceutical companies. Its purpose-built facility is designed to accommodate both biologic and small molecule production, focusing on small-scale injectable products. Symbiosis differentiates itself by offering rapid access to manufacturing slots and quick release of drug products, enabling clients to meet tight timelines effectively. By maintaining high standards of regulatory compliance, Symbiosis supports the evolving needs of its clients in the pharmaceutical sector.

Metrion Biosciences Ltd is a contract research organization based in Cambridge, United Kingdom, specializing in drug discovery services for pharmaceutical and bioscience clients globally. Established in 2015, the company provides a range of preclinical screening services, with a focus on ion channel screening, cardiac safety profiling, neuroscience assays, and translational assays. Metrion's platform offers skilled electrophysiology services in various formats, supporting medicinal chemistry optimization. The organization employs flexible business models, allowing clients to choose between fee-for-service and collaborative options, as well as access to integrated drug discovery services tailored to the specific needs of each program.

Eagle Genomics Ltd., established in 2008, specializes in data management and analysis solutions for the life sciences industry. Based in Cambridge, UK, with offices in the US, Germany, and India, the company caters to healthcare, pharmaceutical, biotech, and personal care sectors. Eagle Genomics offers a suite of services, including NGS data management, analysis, and visualization; cloud computing for bioinformatics; biomarker discovery; and custom software development. Its flagship product, ElasticAP, is a web-based platform for managing life sciences R&D data in the cloud. The company also provides pipeline design services and Eagle On-Demand contracts to assist bioinformatics teams. By leveraging its unique blend of biological, bioinformatics, data science, and enterprise software engineering expertise, Eagle Genomics helps life science companies maximize the value of their R&D data, reducing costs and accelerating research.

Cobra Biologics Limited specializes in contract manufacturing services for biologics and pharmaceuticals, catering to pre-clinical, clinical, and commercial supply needs. The company offers a comprehensive range of services, including cell line development, GMP cell banking, stability testing, protein characterization, and various analytical services. It focuses on producing mammalian and microbial proteins, along with cGMP virus services essential for gene therapy and vaccine production. Cobra Biologics also provides plasmid DNA services, encompassing both non-GMP and GMP processes, and has expertise in aseptic pharmaceutical manufacturing, freeze-drying, and injectable product filling. With facilities in Keele, United Kingdom, and Södertälje, Sweden, the company has built a strong reputation in the global life sciences sector, supporting the development and commercialization of drugs through a combination of integrated and stand-alone services. Founded in 1992 and formerly known as RecipharmCobra Biologics Limited, Cobra Biologics operates as a subsidiary of Cognate BioServices, Inc.

Ixaka is a private UK-based cell and gene therapy company with operations in the UK, Spain, and France. The company leverages proprietary technologies to enhance the body's natural ability to heal, focusing on the development of advanced cell-based therapeutics for serious diseases. Ixaka's innovative approaches include concentrated multi-cell therapies and targeted nanoparticles that aim to deliver curative cells directly to the site of disease and improve their therapeutic efficacy. This platform has potential applications across a variety of conditions, including oncology, cardiovascular, neurological, ocular diseases, and genetic disorders. The ultimate goal of Ixaka's therapies is to reduce pain, improve mobility, and enhance overall patient outcomes.

Domainex Ltd. is a biotechnology company based in Saffron Walden, United Kingdom, that specializes in contract research and manufacturing services focused on drug discovery. Established in 2001, the company provides a comprehensive range of services, including medicinal and computational chemistry, protein expression and purification, biochemical assay development, and DMPK analysis. Domainex is known for its expertise in developing advanced medicines through innovative technologies, including biochemical binding techniques, particularly for oncology drugs and treatments for inflammatory diseases. The company has a significant emphasis on hit identification and candidate drug synthesis, utilizing both virtual and fragment-based approaches to address complex drug discovery challenges. In 2007, Domainex merged with NCE Discovery, enhancing its capabilities in both biological and chemical research.

Oxford BioMedica is a biopharmaceutical company based in Oxford, United Kingdom, specializing in the research, development, and manufacturing of lentiviral vector and cell therapy products for various diseases. The company operates through two main segments: Platform and Product. Its LentiVector platform technology enables the integration of therapeutic genes into non-dividing cells, making it suitable for treating conditions affecting the brain and eyes. Oxford BioMedica's product pipeline includes several candidates in various stages of development, targeting diseases such as hematological tumors, age-related macular degeneration, and central nervous system disorders. Additionally, the company has established partnerships with notable firms like Novartis and Bristol Myers Squibb to advance its therapeutic offerings. Oxford BioMedica also focuses on growing its bioprocessing services, leveraging its technologies to provide revenue-generating solutions for third-party clients, while continuing to innovate in gene and cell therapy. Founded in 1995, the company has positioned itself as a leader in the field of gene therapy, addressing unmet medical needs through its advanced therapeutic candidates.

Bicycle Therapeutics is a clinical-stage biopharmaceutical company focused on developing a novel class of medicines known as Bicycles, which are synthetic short peptides designed to stabilize their structural geometry through two loops. The company primarily targets oncology indications with significant unmet medical needs. Its lead product candidate, BT1718, is a Bicycle Toxin Conjugate currently undergoing Phase I/IIa clinical trials aimed at tumors expressing Membrane Type 1 matrix metalloprotease. Other oncology candidates include BT5528, also in Phase I/IIa trials targeting EphA2, and BT8009, which is in preclinical studies for Nectin-4. Additionally, Bicycle Therapeutics is developing THR-149, a plasma kallikrein inhibitor that has completed Phase I trials for diabetic macular edema. The company collaborates with various biopharmaceutical organizations to advance programs in areas like anti-infectives and cardiovascular health. Founded in 2009, Bicycle Therapeutics is headquartered in Cambridge, United Kingdom.

Spoonful of Sugar Ltd. specializes in providing evidence-based adherence solutions for healthcare providers and the life sciences industry. The company focuses on optimizing medication access and enhancing adherence through intelligent medicines engagement programs. By delivering tailored services, Spoonful of Sugar aims to improve stakeholder concordance and overall health outcomes. Their work involves consulting on medicines-related behavior, enabling clients to gain a deeper understanding of the factors that influence medication adherence. Through these initiatives, Spoonful of Sugar seeks to support both healthcare providers and the pharmaceutical industry in achieving better patient care.

Spirea Ltd. is a healthcare technology company based in Harrogate, United Kingdom, that specializes in developing antibody drug conjugates (ADCs) for cancer treatment. Founded in 2015, Spirea has created a smart polymer platform designed for the controlled delivery of drug combinations, thereby maximizing the clinical efficacy of therapies. The company's innovative approach to ADCs allows for a greater amount of drug payload to be specifically targeted to tumor cells, resulting in enhanced therapeutic effects while significantly minimizing side effects. This development enables healthcare providers to offer well-tolerated treatment options for a variety of cancers, ultimately aiming to improve the quality of life for patients.

CN Bio Innovations Ltd, established in 2008 and headquartered in Cambridge, UK, specializes in developing and providing Organ-on-Chip devices to pharmaceutical and biotech companies. These devices enable more accurate preclinical drug testing by replicating human organ functions in vitro. CN Bio's offerings include microphysiological systems and consumables, used to analyze novel compounds, assess toxicity and safety, and support research scientists in various fields such as oncology, infectious diseases, metabolism, and inflammation. The company's flagship product, the LiverChip platform, features a full viral lifecycle model of hepatitis B, currently employed in drug discovery collaborations with leading pharmaceutical and biotech companies. CN Bio's work is backed by prestigious grants and partnerships with academic institutions, aiming to accelerate the development of breakthrough therapies for serious human diseases.

Xerion Healthcare Limited, founded in 2015 and based in Thame, United Kingdom, specializes in developing and commercializing innovative nanoparticle treatments aimed at improving cancer care. The company focuses on utilizing titanium dioxide nanoparticles, which are injected into tumors prior to standard radiotherapy. This method enhances the effectiveness of radiotherapy by amplifying the dose of free radicals generated by X-rays, allowing for more effective treatment of dense tumors. Xerion Healthcare is currently advancing its technology for head, neck, and pancreatic cancers, with the goal of improving patient outcomes while minimizing side effects associated with conventional cancer treatments.

CHAIN Biotechnology Ltd. is a biotechnology company that specializes in developing and utilizing Clostridium bacteria for various applications, leveraging recent advancements in synthetic biology and automation to enhance fermentation processes. The company focuses on producing chiral chemicals, which are essential for a variety of products such as nutraceuticals, personal healthcare items, pharmaceuticals, and fragrances. Among its key developments are 3-hydroxybutyrate, a versatile chiral molecule, and (R)-methyl-3HB, a precursor chemical for the glaucoma treatment dorzolamide. Additionally, CHAIN Biotechnology is exploring cost-effective fermentation methods using sugar as a substrate. The company's expertise encompasses microbiology, molecular biology tools, and microbial strain development. Founded in 2014 and headquartered in London, United Kingdom, CHAIN Biotechnology is also engaged in developing therapeutic compounds aimed at addressing chronic gut-related diseases through its innovative drug development platform.

Themis Bioscience N.V. is a clinical-stage biopharmaceutical company based in Vienna, Austria, specializing in immunomodulation to develop products aimed at protecting against infectious diseases. Founded in 2009, the company’s lead candidate, MV-CHIK, has successfully completed Phase II clinical trials for chikungunya treatment. Themis is also advancing vaccines targeting other infectious diseases, including Zika virus, Lassa fever, and MERS, along with developing therapeutics for cancer. Themis has established a research collaboration and exclusive licensing agreement with Merck & Co., enhancing its capabilities and market reach. The company is focused on progressing its innovative vaccine candidates through various clinical development phases while positioning itself as a valuable partner in the biotech and pharmaceutical sectors.

Eagle Genomics Ltd., established in 2008, specializes in data management and analysis solutions for the life sciences industry. Based in Cambridge, UK, with offices in the US, Germany, and India, the company caters to healthcare, pharmaceutical, biotech, and personal care sectors. Eagle Genomics offers a suite of services, including NGS data management, analysis, and visualization; cloud computing for bioinformatics; biomarker discovery; and custom software development. Its flagship product, ElasticAP, is a web-based platform for managing life sciences R&D data in the cloud. The company also provides pipeline design services and Eagle On-Demand contracts to assist bioinformatics teams. By leveraging its unique blend of biological, bioinformatics, data science, and enterprise software engineering expertise, Eagle Genomics helps life science companies maximize the value of their R&D data, reducing costs and accelerating research.

Sentinel Oncology Limited is a drug discovery company based in Cambridge, United Kingdom, founded in 2005. The company focuses on developing and commercializing therapeutics aimed at treating cancer, particularly for patients facing unmet medical needs. Sentinel Oncology's research and development pipeline includes innovative programs such as a treatment targeting Checkpoint Kinase 1, which is activated in response to DNA damage and replication stress, and a novel approach to treating metastatic breast cancer through the inhibition of S6K1. The company is advancing a strategy known as "Targeted Synergy," designed to enhance the therapeutic index by delivering drug effects directly to tumors. By fostering partnerships with the biotechnology and pharmaceutical industries, Sentinel Oncology aims to maximize the value of its drug candidates and contribute to improved cancer treatments.

Plasticell is a biotechnology company focused on developing innovative therapeutics through advanced cell culture and drug discovery platforms. The company specializes in elucidating the biochemical mechanisms that regulate the proliferation and differentiation of stem cells, which are essential for tissue development and repair. By testing a wide range of cell culture variables, Plasticell aims to establish optimal laboratory protocols for various applications in cell biology, gene transduction, protein production, and drug screening. This approach enables researchers to create novel small molecule drugs that promote regenerative medicine and improve therapeutic outcomes.

Small Pharma Ltd. is a pharmaceutical company founded in 2015 and headquartered in London, United Kingdom. The company specializes in developing a rapid-acting antidepressant aimed at treating patients with depression. Small Pharma employs a scalable model of outsourced drug development, utilizing expert teams to design and execute development programs. This approach leverages academic discoveries and focuses on effective intellectual property design, ensuring that the various disciplines essential for successful drug development are addressed by qualified professionals.

Elasmogen Ltd is a biopharmaceutical company based in Aberdeen, United Kingdom, focused on developing innovative therapies for inflammatory eye diseases and other autoimmune conditions. The company specializes in soloMERs, which are small, stable proteins derived from variable new-antigen receptors (VNARs) found in sharks. These next-generation therapeutics are unique due to their evolutionary lineage, allowing them to bypass the complex patent landscape associated with traditional antibodies. Elasmogen's pipeline includes programs aimed at autoimmune-mediated inflammation, as well as soloMER-drug conjugates designed for enhanced therapeutic delivery. Additionally, the company has developed NDure, a humanized clinical candidate that extends the plasma half-life of fused partner molecules. Elasmogen holds a strong intellectual property position with over 20 granted patents in various regions, supported by strategic partnerships with Almac Discovery Ltd and Merck Inc. Founded in 2014, the company is dedicated to advancing the treatment options available for patients suffering from sight-threatening and inflammatory diseases.

Autifony Therapeutics Limited is a biotechnology company based in London, United Kingdom, focused on developing innovative medicines for hearing disorders, including hearing loss and tinnitus. Established in 2011, the company leverages a drug discovery platform aimed at addressing unmet medical needs in this area. In addition to its primary focus on hearing-related conditions, Autifony's platform is also designed to alleviate symptoms associated with central nervous system disorders such as schizophrenia, fragile X syndrome, and Alzheimer's disease. By concentrating on these conditions, Autifony Therapeutics aims to provide effective treatment options for patients suffering from a range of debilitating disorders.